Baseline demographic and laboratory characteristics of patients with HCC who reduce the dose of or stop sorafenib. | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 29 April 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2025.371668.1928 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
ُEnas Kamal1; Nourhan Osama Mady  2; Haitham Abdelhamid Mahmoud3
| ||||
| 1Endemic department, faculty of medicine, Minia university, Minia. Egypt | ||||
| 2Department of Hepatology, Gastroenterology and Endemic Diseases, Faculty of Medicine, Minia university, ,El Minia, Egypt | ||||
| 3Endemic medicine department,faculty of medicine,minia university, minia,Egypt | ||||
| Abstract | ||||
| Background: One kind of primary liver cancer is hepatocellular carcinoma, or HCC. When it comes to primary liver cancer, HCC is the culprit responsible for 90% of instances. Patient demographics and laboratory data related to hepatocellular carcinoma (HCC) patients who are unable to tolerate systemic treatment will be collected as part of this study. Methods: Patients with HCC who are eligible for systemic therapy and attend the HCC clinic at Minia University Hospital are included in this prospective study. Our analysis categorized 117 cases into: Group A (Study group): 58 cases who were given a lower dose of sorafenib or stopped taking it altogether while taking treatment. There are 59 patients in Group B, who are considered to be in the control group, and they are the ones who keep taking their medication as prescribed. Results showed that the only patients' comorbidities (diabetes and hypertension) were linked to dose reduction or sorafenib discontinuation or reduction in dosage, when looking at baseline demographic and laboratory data from the study and control groups. Regarding the patients' laboratory data, there was no statistically significant difference between the groups (P value > 0.05). Conclusion: Reducing or discontinuing sorafenib dosage was connected with patients' comorbidities (DM and hypertension), according to our study's conclusion. Reducing or stopping sorafenib did not correlate with any of the laboratory measures of the groups that were investigated. | ||||
| Keywords | ||||
| Hepatocellular Carcinoma; Sorafenib; HCC; Systemic therapy | ||||
|
Statistics Article View: 49 |
||||
